Cobalamin‐Related Remethylation Disorders: Pregnancy Outcomes and Prenatal Treatment‐New Cases and a Literature Study
Authors:
- Karolina M. StepienKSKarolina M. Stepien
- Jolanta Sykut‐CegielskaJSJolanta Sykut‐Cegielska
- Jennifer SloanJSJennifer Sloan
- Flavia PiazzonFPFlavia Piazzon
- Sarah BickSBSarah Bick
- Edwin C. FerrenEFEdwin C. Ferren
- Nina GoldNGNina Gold
- Apolline ImbardAIApolline Imbard
- Mirian C. H. JanssenMJMirian C. H. Janssen
- Pavel JesinaPJPavel Jesina
- Lisa A. JosephLJLisa A. Joseph
- 26 August 2026
- journal article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 49 (5)
Abstract
Cobalamin‐related remethylation disorders (cbl‐RD) are rare, heterogenous conditions with a wide phenotypic spectrum, including prenatal and early infantile manifestations. Data on pregnancy outcomes in affected women and the efficacy and safety of prenatal treatment of affected fetuses remain limited. Here we report (1) five women with cbl‐RDs (3 cblC/epi‐cblC, 1 cblD, 1 cblE) who had in total nine pregnancies and (2) eight fetuses with cbl‐RD (7 cblC, 1 cblF) diagnosed and treated prenatally. All affected mothers were treated with hydroxocobalamin (OHCbl) during pregnancy and two also received betaine and carnitine. Complications included three preterm deliveries and nephrotic‐range proteinuria in one previously undiagnosed mother with cblE. All offspring had favourable outcomes. In pregnancies with affected fetuses, OHCbl was administered to the mother between gestational weeks 5 and 32 at varying doses. Prenatally treated cblC cases exhibited attenuated phenotypes without microcephaly, epilepsy, or severe multisystemic disease. Notably, three of five infants harbouring severe MMACHC variants, who received high‐dose pre‐ and postnatal OHCbl, exhibited normal neurodevelopment and no maculopathy up to age 2–3 years, though variability in genotype, treatment regimens, and duration of follow‐up limit generalizability. A literature review identified nine additional pregnancies in women with cbl‐RD and seven prenatally treated fetuses, with follow‐up available for three. Collectively, our main findings support the safety of maternal and fetal OHCbl treatment during pregnancy. We recommend that when combined with preconception counselling, early standardized diagnosis, optimal monitoring and postnatal care, prenatal OHCbl therapy can improve pregnancy outcomes and mitigate neurodevelopmental and ophthalmic complications in cbl‐RD.Keywords
Funding Information
- National Institutes of Health (1ZIAHG200318)
- National Institutes of Health (BBMRI_CZ LM2023033)
- National Institutes of Health (NU23‐07‐00383)
This publication has 78 references indexed in Scilit:
- First Revision of the Guidelines for the Diagnosis and Management of Remethylation DisordersJournal of Inherited Metabolic Disease, 2026
- Cystathionine β‐Synthase Deficiency in the E‐HOD Registry—Part II: Dietary and Pharmacological TreatmentJournal of Inherited Metabolic Disease, 2025
- Improved biochemical and neurodevelopmental profiles with high‐dose hydroxocobalamin therapy in cobalamin C defectJournal of Inherited Metabolic Disease, 2024
- Clinical and biochemical outcomes in cobalamin C deficiency with use of high‐dose hydroxocobalamin in the early neonatal periodAmerican Journal of Medical Genetics Part A, 2022
- Prenatal diagnosis of combined methylmalonic acidemia and homocystinuria cobalamin C type using clinical exome sequencing and targeted gene analysisMolecular Genetics & Genomic Medicine, 2021
- Cobalamin deficiency in pregnancyClinical Case Reports, 2021
- Outcomes of patients with cobalamin C deficiency: A single center experienceJIMD Reports, 2020
- Clinical and molecular characterization of adult patients with late‐onset MTHFR deficiencyJournal of Inherited Metabolic Disease, 2020
- Parenteral hydroxocobalamin dose intensification in five patients with different types of early onset intracellular cobalamin defects: Clinical and biochemical responsesJIMD Reports, 2019
- Spectrum of mutations inMMACHC, allelic expression, and evidence for genotype–phenotype correlationsHuman Mutation, 2009